Aberrant hypomethylation-mediated CD147 overexpression promotes aggressive tumor progression in human prostate cancer

Oncology Reports

Volumn 33, Issue 5, 2015, Pages 2648-2654

  Liang, Yu Xiang ^a   Mo, Ru Jun ^a   He, Hui Chan ^a   Chen, Jia Hong ^a   Zou, Jun ^a   Han, Zhao Dong ^a   Lu, Jian Ming ^a   Cai, Chao ^a   Zeng, Yan Ru ^a   Zhong, Wei De ^a,b   Wu, Chin Lee ^c  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

CD147; DNA methylation; Prostate cancer; Tumor progression; Tumorigenesis

Indexed keywords

CD147 ANTIGEN; GELATINASE A; BSG PROTEIN, HUMAN; MESSENGER RNA;

ANTIGEN EXPRESSION; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CD147 GENE; CONTROLLED STUDY; CORRELATIONAL STUDY; CPG ISLAND; DISEASE ASSOCIATION; DNA METHYLATION; DNA SEQUENCE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR GROWTH; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; MALE; MOLECULAR GENETICS; PATHOLOGY; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

ANTIGENS, CD147; BASE SEQUENCE; CARCINOGENESIS; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 84927138940     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3870     Document Type: Article

References (27)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013.
2. Molitierno J, Evans A, Mohler JL, Wallen E, Moore D and Pruthi RS: Characterization of biochemical recurrence after radical prostatectomy. Urol Int 77:130-134, 2006.
3. Klotz L: Hormone therapy for patients with prostate carcinoma. Cancer 88(Suppl 12):3009-3014, 2000.
4. Schoenborn JR, Nelson P and Fang M: Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin Cancer Res 19:4058-4066, 2013.
5. Sharma S and Watabe K: Biomarkers and mechanisms associated with recurrent prostate cancer. Front Biosci (Landmark Ed) 19:339-351, 2014.
6. Devaney JM, Wang S, Funda S, Long J, Taghipour DJ, Tbaishat R, Furbert-Harris P, Ittmann M and Kwabi-Addo B: Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia. Prostate Cancer Prostatic Dis 16:292-300, 2013.
7. Yang B, Bhusari S, Kueck J, Weeratunga P, Wagner J, Leverson G, Huang W and Jarrard DF: Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer. Neoplasia 15:399-408, 2013.
8. Lin PC, Giannopoulou EG, Park K, Mosquera JM, Sboner A, Tewari AK, Garraway LA, Beltran H, Rubin MA and Elemento O: Epigenomic alterations in localized and advanced prostate cancer. Neoplasia 15:373-383, 2013.
9. Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, Esopi D, Irizarry RA, Getzenberg RH, Nelson WG, et al: DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med 5:169ra10, 2013.
10. Majumdar S, Buckles E, Estrada J and Koochekpour S: Aberrant DNA methylation and prostate cancer. Curr Genomics 12:486-505, 2011.
11. Dimitriadis E, Kalogeropoulos T, Velaeti S, Sotiriou S, Vassiliou E, Fasoulis L, Klapsas V, Synesiou M, Apostolaki A, Trangas T, et al: Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer. Anticancer Res 33:191-197, 2013.
12. Yu YP, Ding Y, Chen R, Liao SG, Ren BG, Michalopoulos A, Michalopoulos G, Nelson J, Tseng GC and Luo JH: Whole.genome methylation sequencing reveals distinct impact of differential methylations on gene transcription in prostate cancer. Am J Pathol 183:1960-1970, 2013.
13. Haldrup C, Mundbjerg K, Vestergaard EM, Lamy P, Wild P, Schulz WA, Arsov C, Visakorpi T, Borre M, Hoyer S, et al: DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J Clin Oncol 31:3250-3258, 2013.
14. Chao C, Chi M, Preciado M and Black MH: Methylation markers for prostate cancer prognosis: A systematic review. Cancer Causes Control 24:1615-1641, 2013.
15. Dietrich D, Hasinger O, Banez LL, Sun L, Van Leenders GJ, Wheeler TM, Bangma CH, Wernert N, Perner S, Freedland SJ, et al: Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. J Mol Diagn 15:270-279, 2013.
16. Kron K, Trudel D, Pethe V, Briollais L, Fleshner N, Van Der Kwast T and Bapat B: Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer. Clin Cancer Res 19:3450-3461, 2013.
17. Vasiljevi. N, Ahmad AS, Beesley C, Thorat MA, Fisher G, Berney DM, Moller H, Yu Y, Lu YJ, Cuzick J, et al: Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer. Prostate Cancer Prostatic Dis 16:35-40, 2013.
18. Gabison EE, Mourah S, Steinfels E, Yan L, Hoang-Xuan T, Watsky MA, De Wever B, Calvo F, Mauviel A and Menashi S: Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas: role in epitheliostromal interactions and matrix metalloproteinase induction. Am J Pathol 166:209-219, 2005.
19. Sun J and Hemler ME: Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 61:2276-2281, 2001.
20. Wang L, Wu G, Yu L, Yuan J, Fang F, Zhai Z, Wang F and Wang H: Inhibition of CD147 expression reduces tumor cell invasion in human prostate cancer cell line via RNA interference. Cancer Biol Ther 5:608-614, 2006.
21. Zhong WD, Han ZD, He HC, Bi XC, Dai QS, Zhu G, Ye YK, Liang YX, Qin WJ, Zhang Z, et al: CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Oncology 75:230-236, 2008.
22. Madigan MC, Kingsley EA, Cozzi PJ, Delprado WJ, Russell PJ and Li Y: The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression. Cancer Immunol Immunother 57:1367-1379, 2008.
23. Hao JL, Cozzi PJ, Khatri A, Power CA and Li Y: CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer. Curr Cancer Drug Targets 10:287-306, 2010.
24. Han ZD, Bi XC, Qin WJ, He HC, Dai QS, Zou J, Ye YK, Liang YX, Zeng GH, Chen ZN, et al: CD147 expression indicates unfavourable prognosis in prostate cancer. Pathol Oncol Res 15:369-374, 2009.
25. Zhong WD, Liang YX, Lin SX, Li L, He HC, Bi XC, Han ZD, Dai QS, Ye YK, Chen QB, et al: Expression of CD147 is associated with prostate cancer progression. Int J Cancer 130:300-308, 2012.
26. Liang L, Major T and Bocan T: Characterization of the promoter of human extracellular matrix metalloproteinase inducer (EMMPRIN). Gene 282:75-86, 2002.
27. Truong M, Yang B, Livermore A, Wagner J, Weeratunga P, Huang W, Dhir R, Nelson J, Lin DW and Jarrard DF: Using the epigenetic field defect to detect prostate cancer in biopsy negative patients. J Urol 189:2335-2341, 2013.